Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Tscan Therapeutics Inc’s stock clocked out at $2.77, down -2.81% from its previous closing price of $2.85. In other words, the price has decreased by -$2.81 from its previous closing price. On the day, 0.74 million shares were traded. TCRX stock price reached its highest trading level at $2.8 during the session, while it also had its lowest trading level at $2.61.
Ratios:
To gain a deeper understanding of TCRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.56 and its Current Ratio is at 9.56. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 16, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.
On June 22, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.Wedbush initiated its Outperform rating on June 22, 2023, with a $8 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 13 ’24 when Lynx1 Capital Management LP bought 100,000 shares for $2.90 per share. The transaction valued at 290,140 led to the insider holds 5,357,347 shares of the business.
Lynx1 Capital Management LP bought 31,800 shares of TCRX for $95,629 on Dec 12 ’24. The 10% Owner now owns 5,257,347 shares after completing the transaction at $3.01 per share. On Nov 15 ’24, another insider, Lynx1 Capital Management LP, who serves as the 10% Owner of the company, bought 947 shares for $4.34 each. As a result, the insider paid 4,114 and bolstered with 5,225,547 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 156519952 and an Enterprise Value of -32927454. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.79 while its Price-to-Book (P/B) ratio in mrq is 0.65. Its current Enterprise Value per Revenue stands at -3.517 whereas that against EBITDA is 0.287.
Stock Price History:
The Beta on a monthly basis for TCRX is 0.90, which has changed by -0.5232358 over the last 52 weeks, in comparison to a change of 0.22263205 over the same period for the S&P500. Over the past 52 weeks, TCRX has reached a high of $9.69, while it has fallen to a 52-week low of $2.60. The 50-Day Moving Average of the stock is -31.39%, while the 200-Day Moving Average is calculated to be -54.38%.
Shares Statistics:
It appears that TCRX traded 391.16K shares on average per day over the past three months and 770790 shares per day over the past ten days. A total of 49.08M shares are outstanding, with a floating share count of 43.51M. Insiders hold about 18.47% of the company’s shares, while institutions hold 74.35% stake in the company. Shares short for TCRX as of 1734048000 were 2346815 with a Short Ratio of 6.44, compared to 1731628800 on 2295860. Therefore, it implies a Short% of Shares Outstanding of 2346815 and a Short% of Float of 5.6199998.
